Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Nivolumab plus relatlimab significantly improved progression-free survival (PFS) in advanced melanoma patients. Updated data show sustained benefits and a favorable safety profile for this combination therapy.
Area Of Science
- Oncology
- Immunotherapy
- Melanoma Research
Background
- The RELATIVITY-047 trial investigated the efficacy of nivolumab plus relatlimab versus nivolumab alone.
- Advanced melanoma remains a significant clinical challenge requiring novel therapeutic strategies.
Purpose Of The Study
- To report updated efficacy and safety findings from the RELATIVITY-047 trial with extended follow-up.
- To assess the long-term benefit of nivolumab plus relatlimab in patients with advanced melanoma.
Main Methods
- Updated analysis of progression-free survival (PFS), overall survival (OS), and objective response rate (ORR).
- Median follow-up of 33.8 months in the RELATIVITY-047 trial (NCT03470922).
- Evaluation of safety and efficacy across predefined subgroups.
Main Results
- Median PFS was 10.2 months with nivolumab plus relatlimab versus 4.6 months with nivolumab (HR, 0.79).
- Median OS was 51.0 months versus 34.1 months, respectively (HR, 0.80), with the OS HR upper bound now <1.
- Objective response rate (ORR) was 43.7% for the combination versus 33.7% for nivolumab alone.
Conclusions
- Nivolumab plus relatlimab demonstrated sustained efficacy in advanced melanoma at 3-year follow-up.
- The combination therapy shows a clinically meaningful and statistically significant improvement in PFS and OS.
- The safety profile remains consistent with previous reports, supporting the use of nivolumab plus relatlimab.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
